FULVESTRANT
Generic: FULVESTRANT
Fresenius Kabi USAManufacturer
INTRAMUSCULARRoute
FULVESTRANTActive Substance
2019-05-20Original Approval
FULVESTRANT is FDA application NDA210326, sponsored by FRESENIUS KABI USA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2021-08-27
Fulvestrant Injection 250 mg/5 mL (50 mg/mL) For Intramuscular Use Only Contains 2 single-dose pre-filled syringes Rx onLack of Assurance of Sterility
Class II2022-07-15
Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx Only, Product of India, ManufaFailed Impurities/Degradation Specifications
Top Reported Reactions
1
MALIGNANT NEOPLASM PROGRESSION
2,842 reports
2
FATIGUE
1,865 reports
3
NEUTROPENIA
1,718 reports
4
NAUSEA
1,598 reports
5
METASTASES TO BONE
1,493 reports
6
DEATH
1,411 reports
7
DIARRHOEA
1,408 reports
8
BREAST CANCER METASTATIC
1,259 reports
9
METASTASES TO LIVER
1,226 reports
10
NEOPLASM PROGRESSION
986 reports